These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 36148870)

  • 1. The Role of PD Biomarkers in Biosimilar Development - To Get the Right Answer One Must First Ask the Right Question.
    Woollett GR; Park JP; Han J; Jung B
    Clin Pharmacol Ther; 2023 Jan; 113(1):50-54. PubMed ID: 36148870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamic Biomarkers for Biosimilar Development and Approval: A Workshop Summary.
    Florian J; Sun Q; Schrieber SJ; White R; Shubow S; Johnson-Williams BE; Sheikhy M; Harrison NR; Parker VJ; Wang YM; Strauss DG
    Clin Pharmacol Ther; 2023 May; 113(5):1030-1035. PubMed ID: 36380593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamic Biomarkers Evidentiary Considerations for Biosimilar Development and Approval.
    Strauss DG; Wang YM; Florian J; Zineh I
    Clin Pharmacol Ther; 2023 Jan; 113(1):55-61. PubMed ID: 36178447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of Availability, Clinical Testing, and US Food and Drug Administration Review of Biosimilar Biologic Products.
    Moore TJ; Mouslim MC; Blunt JL; Alexander GC; Shermock KM
    JAMA Intern Med; 2021 Jan; 181(1):52-60. PubMed ID: 33031559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The US approach to biosimilars: the long-awaited FDA approval pathway.
    Calvo B; Zuñiga L
    BioDrugs; 2012 Dec; 26(6):357-61. PubMed ID: 23030677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of Pharmacokinetic and Pharmacodynamic Parameters in EU- Versus US-Licensed Reference Biological Products: Are In Vivo Bridging Studies Justified for Biosimilar Development?
    Tu CL; Wang YL; Hu TM; Hsu LF
    BioDrugs; 2019 Aug; 33(4):437-446. PubMed ID: 31111423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of biosimilars.
    Al-Sabbagh A; Olech E; McClellan JE; Kirchhoff CF
    Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S11-8. PubMed ID: 26947440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Considerations related to comparative clinical studies for biosimilars.
    Rathore AS; Stevenson JG; Chhabra H
    Expert Opin Drug Saf; 2021 Mar; 20(3):265-274. PubMed ID: 33455482
    [No Abstract]   [Full Text] [Related]  

  • 9. Biosimilars: A consideration of the regulations in the United States and European union.
    Daller J
    Regul Toxicol Pharmacol; 2016 Apr; 76():199-208. PubMed ID: 26732800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving the power to establish clinical similarity in a Phase 3 efficacy trial by incorporating prior evidence of analytical and pharmacokinetic similarity.
    Zeng D; Pan J; Hu K; Chi E; Lin DY
    J Biopharm Stat; 2018; 28(2):320-332. PubMed ID: 29173074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leveraging Clinical Pharmacology Data to Assess Biosimilarity and Interchangeability of Insulin Products.
    Vaidyanathan J; Wang YC; Tran D; Seo SK
    Clin Pharmacol Ther; 2023 Apr; 113(4):794-802. PubMed ID: 36052570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of the EU Biosimilar Framework: Past and Future.
    Wolff-Holz E; Tiitso K; Vleminckx C; Weise M
    BioDrugs; 2019 Dec; 33(6):621-634. PubMed ID: 31541400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survey of Data Package and Sample Size of Comparative Clinical Studies for Biosimilar Developments from PMDA Assessments.
    Kuribayashi R; Hariu A; Nakano A; Kishioka Y
    Pharmaceut Med; 2024 May; 38(3):225-239. PubMed ID: 38684588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analytic characterization of biosimilars.
    Sullivan PM; DiGrazia LM
    Am J Health Syst Pharm; 2017 Apr; 74(8):568-579. PubMed ID: 28389456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biosimilars: The US Regulatory Framework.
    Christl LA; Woodcock J; Kozlowski S
    Annu Rev Med; 2017 Jan; 68():243-254. PubMed ID: 27813877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases.
    Braun J; Kudrin A
    Immunotherapy; 2015; 7(2):73-87. PubMed ID: 25713985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interchangeability of Biosimilars: What Level of Clinical Evidence is Needed to Support the Interchangeability Designation in the United States?
    Alvarez DF; Wolbink G; Cronenberger C; Orazem J; Kay J
    BioDrugs; 2020 Dec; 34(6):723-732. PubMed ID: 32990892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biosimilarity assessment of biosimilar therapeutic monoclonal antibodies.
    Ishii-Watabe A; Kuwabara T
    Drug Metab Pharmacokinet; 2019 Feb; 34(1):64-70. PubMed ID: 30600193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The road from development to approval: evaluating the body of evidence to confirm biosimilarity.
    Declerck P; Farouk Rezk M
    Rheumatology (Oxford); 2017 Aug; 56(suppl_4):iv4-iv13. PubMed ID: 28903545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical trials for authorized biosimilars in the European Union: a systematic review.
    Mielke J; Jilma B; Koenig F; Jones B
    Br J Clin Pharmacol; 2016 Dec; 82(6):1444-1457. PubMed ID: 27580073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.